Eli Lilly signs a deal worth up to $1.1 billion with a Chinese AI drug-delivery company

Metis TechBio said on Monday, Oct. 19, 2026, that it has entered a strategic collaboration with Eli Lilly to discover new lipid nanoparticle (LNP) delivery systems designed to send therapies to specific tissues, using its AI-driven AiLNP platform, in a deal worth up to about $1.1 billion in milestones.

Big pharma's AI deals keep following the same shape: a small check now, a billion-dollar headline later if things work. Here the upfront is in the tens of millions; the $1.1 billion only arrives if molecules clear development, regulators and the market. The interesting part is the target. Delivery, not the drug, is often the bottleneck — an mRNA or gene therapy is only as good as the vehicle that gets it to the right cells. Lilly is paying to see if an AI that designs lipids can steer those vehicles past the liver. It's also a US drug giant striking a deal with a Chinese AI biotech the same day Washington ordered a Chinese AI model out of federal systems, which tells you the two worlds don't run on the same rules yet.

Metis TechBio (HKEX: 7666), a Beijing-incorporated company listed in Hong Kong, announced a strategic collaboration with Eli Lilly focused on research and discovery of novel lipid nanoparticle-based delivery solutions designed to send therapies to specific tissues. Lipid nanoparticles, or LNPs, are tiny fat bubbles that can carry a drug or genetic medicine into cells. Those terms are Metis's, as filed with the Hong Kong exchange.

On the money: Metis is eligible for an upfront payment "in the low double-digit millions of U.S. dollars," up to about $1.1 billion in development, regulatory and commercial milestone payments, and single-digit tiered royalties on annual net sales of resulting products. A milestone is an extra check if a program hits a later goal. A royalty is a share of later sales. Almost all of the $1.1 billion depends on those later steps. It is not cash Metis has been paid. Those economics are Metis's.

Metis will use its proprietary AI-driven ionizable lipid discovery and optimization platform, AiLNP, to develop delivery technologies that could improve the targeting and biodistribution of LNP-based delivery. Ionizable lipids are the fat molecules that help an LNP get into a cell. Biodistribution is where the payload actually ends up in the body. Lilly contributes drug discovery, development and commercialization expertise. The companies say they will combine Metis's "generative and predictive AI for rational LNP design" with Lilly's expertise, across multiple disease areas. No target disease, drug or Lilly program was named. Those lines are the companies', as Metis prints them. Lilly did not issue its own statement in the announcement.

As simple background, not a claim from the companies: lipid nanoparticles are the same class of fat bubble that carried the mRNA in COVID-19 vaccines. Most LNPs used today end up mainly in the liver, which is why steering them to other tissues is a prize.

About Metis, from its announcement: it was co-founded in 2020 by Dr. Hongming Chen, a member of the U.S. National Academy of Engineering, with MIT scientists Dr. Tsai-Ta Lai, now chairman and CEO, and Dr. Wenshou Wang. It listed in Hong Kong on May 13, 2026, and bills itself as the "world's first listed company of AI drug delivery." It says it has a proprietary library of more than 10 million lipids and has achieved targeted delivery to eight organs or tissues, including the liver, lungs, muscles and immune cells. Those lines are Metis's claims.

In plain terms, Metis said on Monday that it struck a research deal with Eli Lilly to use its AiLNP software to design fat-bubble carriers that aim drugs at specific tissues. The cash up front is in the tens of millions of dollars. The $1.1 billion headline is a stack of later milestones and a slice of sales if products result. No disease, no drug and no Lilly program was named.